
	Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient&rsquo;s own immune system to fight tumor cells. Kite&rsquo;s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI&rsquo;s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year&rsquo;s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin&rsquo;s lymphoma, with additional filings expected for other eACT&trade; products in diverse oncology indications.
